Galactosidase Market Size Worth USD 2.90 Billion 2032 | Emergen Research

The global galactosidase market size was USD 1.58 Billion in 2022 and is expected to register a rapid revenue CAGR of 6.3% during the forecast period. In the rapidly evolving landscape of enzyme technology, the global galactosidase market is experiencing significant expansion, fueled by the burgeoning demand from the Food & Beverage (F&B) industry and medical sectors. Galactosidase enzymes, renowned for their ability to catalyze the hydrolysis of galactosides into monosaccharides, particularly alpha-galactosidase and beta-galactosidase, are playing a pivotal role across various high-tech industries and specialized applications.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/2854

Key Market Drivers:

The escalating adoption of galactosidase in the F&B industry for lactose hydrolysis and the production of lactose-free goods is a primary driver of market revenue growth. This surge in demand stems from the need to minimize crystallization in products like ice creams and condensed milk, thereby enhancing product quality.

Moreover, the rising prominence of galactosidase in medical applications, such as blood group conversion and enzyme replacement therapies, is contributing to market expansion. For instance, the recent approval of Elfabrio and Pegnigalsidase Alpha for the treatment of Fabry disease underscores the growing significance of galactosidase in healthcare.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/2854

Market Restraints:
Despite the promising growth prospects, certain factors pose challenges to market expansion. Concerns regarding side effects associated with alpha-galactosidase drugs and supply-demand imbalances could hinder revenue growth. Furthermore, the intricate production process of galactosidase, which involves precise lactose hydrolysis and stringent quality control measures, contributes to increased operational costs, prompting potential buyers to explore cost-effective alternatives.

Segment Insights:

Galactosidase Product Dynamics:
- The alpha galactosidase segment dominates the market, driven by its widespread use in animal feed and wine-making industries. Its resistance to inhibitors and effectiveness in carbohydrate digestion make it a preferred choice in various applications.

- The beta galactosidase segment is also gaining traction, albeit to a lesser extent, owing to its diverse applications in food processing and pharmaceuticals.

Galactosidase Form:
Capsules are witnessing steady growth, particularly in medical applications such as the treatment of genetic disorders like Fabry disease. The precise control over purification processes makes capsule galactosidase an attractive option for manufacturers seeking therapeutic solutions.

Galactosidase Application:
The Food and Beverages segment commands a significant market share, driven by the increasing demand for lactose-free products. Galactosidase's ability to hydrolyze lactose and maintain product quality under harsh conditions is driving its adoption in beverage production and wine-making.

Direct Order Can Be Placed Through This Link [Exclusive Copy] @ https://www.emergenresearch.com/select-license/2854

Major Companies and Competitive Landscape
The global galactosidase market is fragmented, with large and medium-sized players accounting for the majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective galactosidase solutions.

Some of the major companies included in the global galactosidase market report are:

• Biocompare
• Megazyme Ltd.
• JINAN BESTZYME BIOENGINEERING CO., LTD.
• Prospec-Tany Technogene Ltd.
• Pharming Group N.V.
• ISU ABXIS
• Protalix Biotherapeutics
• Chiesi Limited
• Aumgene Biosciences
• Amano Enzyme, Inc.
• Novozymes
• Bestochem
• DuPont
• Konochem Co., Ltd.
• Sangamo Therapeutics, Inc.

Strategic Development
• On 5 May 2023, Chiesi announced the signing of Global Rare Strategies, a business unit of the Chiesi Group that provides innovative treatments and solutions for people with rare diseases. Protalix BioTherapeutics, Inc. ProCellEx enriches therapeutic proteins expressed through the proprietary plant cell-based expression system ProCellEx, which the European Commission (EC) has approved in the European Union (EU) for treatment of adult Fabry disease patients with PRX-102 (pegnigalsidase alfa) has been granted marketing approval.

• On 22 February 2023, Sangamo Therapeutics, Inc., a genomic medicine company, announced updated preliminary data as of October 20, 2022, from the Phase 1/2 clinical study of STAAR evaluates isaralgagene civaparvovec, or ST-920, a wholly owned Gene therapy product candidate for the treatment of Fabry disease.

For the purpose of this report, Emergen Research has segmented the global galactosidase market on the basis of product, form, application, and region:

• Product Outlook (Revenue, USD Billion; 2019-2032)
o Alpha Galactosidase
o Beta Galactosidase

• Form Outlook (Revenue, USD Billion; 2019-2032)
o Capsule
o Tablet
o Others

• Application Outlook (Revenue, USD Billion; 2019-2032)
o Food & Beverages (F&B)
o Pharmaceuticals
o Pulp and Paper
o Feed
o Others

• Regional Outlook (Revenue, USD Billion; 2019-2032)
o North America
1. U.S.
2. Canada
3. Mexico
o Europe
1. Germany
2. France
3. UK
4. Italy
5. Spain
6. Benelux
7. Rest of Europe
o Asia Pacific
1. China
2. India
3. Japan
4. South Korea
5. Rest of APAC
o Latin America
1. Brazil
2. Rest of LATAM
o Middle East & Africa
1. Saudi Arabia
2. UAE
3. South Africa
4. Turkey
5. Rest of Middle East & Africa

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/galactosidase-market

Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

About Us:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

This release was published on openPR.